Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …

Patients with breast tumors that do not express the estrogen receptor, the progesterone
receptor, nor Her-2/neu are hence termed “triple negatives”, and generally have a poor …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor,
human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is …

Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A
subset of TNBC is immune activated, suggesting that immunotherapy may be a viable …

Purpose Immunotherapy has started to transform the treatment of triple-negative breast
cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …